No connection

Search Results

BIAF vs QUCY

BIAF
bioAffinity Technologies, Inc.
BEARISH
Price
$1.35
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
QUCY
Mainz Biomed N.V.
BEARISH
Price
$0.49
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BIAF
--
QUCY
--
Forward P/E
BIAF
-2.25
QUCY
--
P/B Ratio
BIAF
0.52
QUCY
7.38
P/S Ratio
BIAF
0.9
QUCY
11.35
EV/EBITDA
BIAF
0.09
QUCY
-0.6

Profitability

Gross Margin
BIAF
27.86%
QUCY
72.58%
Operating Margin
BIAF
-158.56%
QUCY
-2159.86%
Profit Margin
BIAF
-217.5%
QUCY
0.0%
ROE
BIAF
-245.18%
QUCY
-488.32%
ROA
BIAF
-71.71%
QUCY
-89.61%

Growth

Revenue Growth
BIAF
-38.5%
QUCY
-32.9%
Earnings Growth
BIAF
--
QUCY
--

Financial Health

Debt/Equity
BIAF
0.08
QUCY
4.01
Current Ratio
BIAF
3.65
QUCY
0.5
Quick Ratio
BIAF
3.44
QUCY
0.27

Dividends

Dividend Yield
BIAF
--
QUCY
--
Payout Ratio
BIAF
0.0%
QUCY
0.0%

AI Verdict

BIAF BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.

Strengths
Strong liquidity position with Current Ratio of 3.65 and Quick Ratio of 3.44
Low leverage with Debt/Equity ratio of only 0.08
Positive gross margin of 27.86%, indicating some pricing power or cost control at production level
Risks
Critically low Piotroski F-Score of 1/9 signals high risk of financial failure
Massive and sustained profitability deficits: Operating Margin of -158.56%, ROA of -71.71%
Revenue declining sharply by 38.5% year-over-year, indicating deteriorating business fundamentals
QUCY BEARISH

QUCY exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.50. The company is suffering from catastrophic operational inefficiency with an operating margin of -2159.86% and a massive ROE of -488.32%. Despite beating negative earnings estimates, the fundamental trend is one of collapse, with revenue declining by 32.90% YoY and a 5-year price depreciation of 98.2%. The combination of high leverage (Debt/Equity 4.01) and shrinking revenues suggests a high risk of insolvency.

Strengths
Strong Gross Margin (72.58%) indicating product value
Recent trend of beating EPS estimates (3/4 quarters)
Positive Q/Q EPS growth (+38.5%) although still deeply negative
Risks
Severe liquidity risk with a Quick Ratio of 0.27
Extreme operational losses (Operating Margin -2159.86%)
Significant revenue contraction (-32.90% YoY)

Compare Another Pair

BIAF vs QUCY: Head-to-Head Comparison

This page compares bioAffinity Technologies, Inc. (BIAF) and Mainz Biomed N.V. (QUCY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile